Alejandro Schwartz
About Alejandro Schwartz
Alejandro Schwartz is a Drug Discovery Scientist at BenevolentAI in Cambridge, England, specializing in assay development and cell-based screening.
Current Position at BenevolentAI
Alejandro Schwartz is currently working as a Drug Discovery Scientist at BenevolentAI in Cambridge, England. He joined the company on March 1, 2021. As part of the in-vitro biology team, his focus is on assay development and cell-based screening. His role involves developing screening methodologies to evaluate the effectiveness and safety of potential drug candidates.
Education and Qualifications
Alejandro Schwartz holds an MBiol (Hons) in Pharmacology. He studied at Nottingham Law School, where he pursued a degree in Biology and successfully achieved a Masters over a four-year period from 2016 to 2020. This academic background provided him with a solid foundation in the biological sciences which he now applies in his professional role.
Expertise in Drug Discovery
As a Drug Discovery Scientist at BenevolentAI, Alejandro Schwartz is part of the in-vitro biology team. His expertise centers around assay development and cell-based screening, key components in the drug discovery process. His role is crucial for identifying and testing new drug candidates, ensuring their potential efficacy before they advance to further stages of development.
Professional Background
Alejandro Schwartz's professional journey in the pharmaceutical industry began on March 1, 2021, when he joined BenevolentAI. Since then, he has been actively involved with the in-vitro biology team, working on assay development and cell-based screening. This position leverages his academic training in pharmacology and biology, applying it to real-world challenges in drug discovery.